EGFR Expressing Solid Tumors Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Tyrosine Kinase Inhibitors (TKIs), and Monoclonal Antibodies (mAbs)), By Cancer Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Head & Neck Cancer, and Others), By Line of Therapy (First Line Therapy, Second Line Therapy, and Lateral Line Therapy), and Region

EGFR Expressing Solid Tumors Treatment Market size was valued at US$ 176.83 billion in 2023 and is poised to grow at a CAGR of 10.3% from 2024 to 2030. The EGFR-expressing solid tumors treatment market is poised for significant growth in the coming years, driven by a confluence of factors that are influencing treatment trends. Economic growth, particularly in developing regions like Asia Pacific, translates to increased healthcare spending. This allows for greater investment in advanced cancer treatments, including EGFR-targeted therapies. In addition, government initiatives and healthcare reforms are improving access to these therapies for patients in some regions. This wider patient pool translates to market expansion. Moreover, the healthcare industry is witnessing a growing emphasis on personalized medicine, which tailors treatment approaches to individual patients based on their specific genetic makeup and tumor characteristics. Also, EGFR mutations are a critical biomarker for determining patient eligibility for EGFR-targeted therapies. The growing adoption of personalized medicine creates a strong demand for EGFR testing and subsequent treatment with these targeted drugs.

Furthermore, pharmaceutical companies are continuously innovating and developing new and improved EGFR inhibitors. These advancements cater to various needs, such as overcoming resistance mutations and offering better efficacy and tolerability profiles. The influx of new-generation EGFR inhibitors with improved characteristics like next-generation tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) broadens treatment options for physicians and improves patient outcomes. This constant pipeline of novel drugs keeps the market vibrant and fosters continued growth. Also regulatory agencies like the US Food and Drug Administration (FDA) are streamlining approval processes for innovative cancer treatments. This expedited approval process allows for faster market access of new EGFR inhibitors, benefitting patients and propelling market growth. Despite a growing market in some developing regions, limited access to EGFR-targeted therapies remains a challenge in many low- and middle-income countries.

EGFR Expressing Solid Tumors Treatment Market Key Developments:

• In February 2024, AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
• In February 2024, AstraZeneca said, it expects Tagrisso monotherapy will continue to be the mainstay treatment in first-line EGFR-mutated NSCLC, while the chemo combo will be reserved for patients with high tumor burden.
• In September 2023, AstraZeneca’s Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial.
• In June 2023, AstraZeneca’s Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial.